吉非替尼治疗非小细胞肺癌生存期长于６个月患者的预后影响因素分析

目的：探讨吉非替尼治疗有效生存期≥6个月的NSCLC患者的预后影响因素。方法选取吉非替尼治疗有效≥6个月且临床资料完整的NSCLC 84例患者临床资料，分析其临床及治疗特征与总生存时间（OS）及无进展生存时间（PFS）的关系。结果患者年龄、就诊时卡氏评分（KPS）与OS及PFS呈正相关，就诊时症状个数与OS及PFS呈负相关。性别、吸烟史、病理类型、初诊时分期，治疗前生存时间与长期生存患者的PFS及OS相关性不大。结论年龄较大、就诊时KPS评分良好的NSCLC患者行吉非替尼口服治疗可能获得更长的OS和PFS，而就诊时症状个数较多者即使初始治疗有效，其OS和PFS也可能较短。

Analysis of prognostic factors in NSCLC patients treated with gefitinib for more than 6 months

Objective To explore the prognostic factors in patients with non-small cell lung cancer (NSCLC)treated with gefitinib for more than 6 months.Methods 64 cases of NSCLC patients treated with gefitinib,which had complete clinical data of more than 6 months,were enrolled in the study.And the relationship between their clinical and therapeutic characteristics and their overall survival (OS) and progression-free survival (PFS)were analyzed.Results Age and Karnofky performance scale (KPS)scores of all patients were posi-tively correlated with their OS and PFS periods,but the number of symptoms was in negative correlation with the OS and PFS.Gender,smok-ing history,pathological type,initial stage,survival time before gefitinib treatment of long-term survival patients had no significant relation-ship with their OS and PFS periods.Conclusion The NSCLC patients with older age or higher KPS score may get longer OS and PFS periods when treated with gefitinib orally.On the contrary,the NSCLC patients with more symptoms would get shorter OS and PFS periods,even if the gefitinib treatment being effective at the beginning.